Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of RGN-259 for Dry Eye Disease

Trial Profile

Clinical study of RGN-259 for Dry Eye Disease

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Timbetasin (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; Diagnostic use
  • Acronyms ARISE-4
  • Sponsors ReGenTree

Most Recent Events

  • 24 Oct 2022 According to a RegeneRx Biopharmaceuticals media release, this trial is expected to begin in Q2 2023.
  • 24 Oct 2022 According to a RegeneRx Biopharmaceuticals media release, company submitted a request for the Special Protocol Assessment (SPA) to the U.S. FDA for an in-depth discussion and assessment of the clinical protocol for this trial.
  • 29 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top